696-08-2

Basic information

• Product Name: 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE
• Synonyms: 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE;4-Chloro-2-methylpyridine N-oxide;4-Chloro-2-picoline 1-oxide;4-chloro-2-methyl-1-oxidopyridin-1-ium;Pyridine,4-chloro-2-methyl-, 1-oxide
• CAS NO: 696-08-2
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 143.57094
• Mol File: 696-08-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE(696-08-2)
• EPA Substance Registry System: 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE(696-08-2)

Safety Data

• Hazardous Substances Data: 696-08-2(Hazardous Substances Data)

Usage

General Description

4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE is a chemical compound with the molecular formula C6H6ClNO. It is a pyridine derivative that contains a chloro and a methyl group attached to the pyridine ring, as well as an oxygen atom in the form of an oxide. 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various organic compounds. Additionally, 4-CHLORO-2-METHYL-PYRIDINE 1-OXIDE can be used as a reagent in organic synthesis and as a precursor in the preparation of other chemical compounds.

Upstream product

• 5470-66-6 2-methyl-4-nitropyridine N-oxide 
• 75-36-5 acetyl chloride 
• 584-08-7 potassium carbonate 

Downstream Products

• 137543-66-9 4-<<4-(trifluoromethyl)benzyl>oxy>-2-picoline N-oxide 
• 10177-21-6 4-chloro-2-chloromethyl pyridine 
• 63071-10-3 (4-chloropyridin-2-yl)methanol 

Relevant articles and documents

Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no small molecule mGlu5 NAM has yet to reach market. Here we present the discovery and evaluation of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (27, VU0424238), a compound selected for clinical evaluation. Compound 27 is more than 900-fold selective for mGlu5 versus the other mGlu receptors, and binding studies established a Ki value of 4.4 nM at a known allosteric binding site. Compound 27 had a clearance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively. Imaging studies using a known mGlu5 PET ligand demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose of 0.06 mg/kg in baboons.

SUBSTITUTED 4-ALKOXYPICOLINAMIDE ANALOGS DS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Molecular complexes of 4-nitropyridine and 4-nitroquinoline N-oxides with boron trifluoride and hydrogen chloride as intermediates in SNAr reactions

Complexation of 4-nitropyridine N-oxides with ν- (BF3, HCl) and π-acceptors (tetracyanoethylene, chloranil, 2,3-dichloro-5,6-dicyano-1,4- benzoquinone, 7,7,8,8-tetracyanoquinodimethane) activates the nitro group to nucleophilic replacement by chlorine. Adducts formed by 4-nitropyridine and 4-nitroquinoline N-oxides with boron trifluoride and hydrogen chloride were studied by IR spectroscopy. It was shown that these complexes belong to the n,ν type and that the donor-acceptor interaction therein involves the oxygen atom of the N-oxide group.